Related Experiment Video
Updated: Nov 28, 2025

A 3D Organotypic Melanoma Spheroid Skin Model
Published on: May 18, 2018
RAGE Signaling in Melanoma Tumors
Olamide T Olaoba1, Sultan Kadasah1, Stefan W Vetter1
1Department of Pharmaceutical Sciences, School of Pharmacy, North Dakota State University, Fargo, ND 58105, USA.
Abstract:
Despite recent progresses in its treatment, malignant cutaneous melanoma remains a cancer with very poor prognosis. Emerging evidences suggest that the receptor for advance glycation end products (RAGE) plays a key role in melanoma progression through its activation in both cancer and stromal cells. In tumors, RAGE activation is fueled by numerous ligands, S100B and HMGB1 being the most notable, but the role of many other ligands is not well understood and should not be underappreciated. Here, we provide a review of the current role of RAGE in melanoma and conclude that targeting RAGE in melanoma could be an approach to improve the outcomes of melanoma patients.
Insights
The receptor for advanced glycation end products (RAGE) is crucial in melanoma progression. Targeting RAGE offers a potential strategy to improve outcomes for melanoma patients.
Area of Science:
- Oncology
- Molecular Biology
- Dermatology
Background:
- Malignant cutaneous melanoma has a poor prognosis despite treatment advances.
- The receptor for advanced glycation end products (RAGE) is implicated in melanoma progression.
- RAGE activation occurs in both cancer and stromal cells within tumors.
Purpose of the Study:
- To review the current role of RAGE in melanoma.
- To highlight the significance of RAGE ligands in melanoma progression.
- To evaluate RAGE as a therapeutic target in melanoma.
Main Methods:
- Literature review of RAGE in melanoma.
- Analysis of RAGE activation pathways and ligands.
- Synthesis of evidence on RAGE's role in tumor progression.
Main Results:
- RAGE activation is a key driver of melanoma progression.
- Numerous ligands, including S100B and HMGB1, fuel RAGE activation.
- The roles of many RAGE ligands in melanoma are not fully understood.
Conclusions:
- Targeting RAGE presents a promising therapeutic strategy for melanoma.
- Further research into RAGE ligands could uncover new therapeutic avenues.
- Modulating RAGE signaling may improve clinical outcomes for melanoma patients.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Abnormal Proliferation
Autocrine Signaling
Autocrine Signaling in Macrophages
Under normal physiological conditions, autocrine signaling is essential for maintaining homeostasis. This process is well characterized in...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...

